CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
Shiro Nakamura, Teita Asano, Hiroaki Tsuchiya, Kanami Sugimoto, Yuya Imai, Seiji Yokoyama, Yasuo Suzuki

DOI: https://doi.org/10.5217/ir.2021.00032

Excel Download

P466 Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i439-i441   Crossref logo
Link1 Link2

Real-world safety and efficacy of twice-daily budesonide 2-mg foam in patients with ulcerative colitis: interim analysis of post-marketing surveillance
Expert Opinion on Pharmacotherapy. 2021;22(11):1505-1511   Crossref logo
Link1

Clinical response among golimumab-treated Japanese patients with rheumatoid arthritis by number of previous biologic therapies: Real-world evidence from post-hoc analysis of post-marketing surveillance data
Modern Rheumatology. 2020;31(3):566-574   Crossref logo
Link1

P453 Golimumab in real-world practice in patients with ulcerative colitis: 2-year interim results from a non-interventional trial in Germany
Journal of Crohn's and Colitis. 2019;13(Supplement_1):S337-S338   Crossref logo
Link1

P350 Real-world data regarding treatment of ulcerative colitis patients with golimumab in Switzerland
Journal of Crohn's and Colitis. 2019;13(Supplement_1):S278-S278   Crossref logo
Link1

P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)
Journal of Crohn's and Colitis. 2020;14(Supplement_1):S394-S394   Crossref logo
Link1 Link2

Real-World Safety and Effectiveness of Canakinumab in Patients with Tumour Necrosis Factor Receptor-Associated Periodic Syndrome or Hyperimmunoglobulinaemia D Syndrome: Interim Results from Post-Marketing Surveillance in Japan
Modern Rheumatology. 2022;   Crossref logo
Link1 Link2

Exam 1: Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis and Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
Gastroenterology. 2014;146(1):e14-e15   Crossref logo
Link1 Link2

Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
Rheumatology and Therapy. 2020;7(2):311-325   Crossref logo
Link1 Link2 Link3

Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
Rheumatology and Therapy. 2020;7(4):1053-1053   Crossref logo
Link1 Link2 Link3